RecruitingPhase 1NCT07368270
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Studying Primary cutaneous diffuse large B-cell lymphoma, leg type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
- Intervention
- Anti-PD1 armored CD19 CAR-T cells(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Suzhou Hongci Hematology Hospital, Suzhou, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07368270 on ClinicalTrials.govOther trials for Primary cutaneous diffuse large B-cell lymphoma, leg type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07059650DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT06570447Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLTianjin Medical University Cancer Institute and Hospital
See all trials for Primary cutaneous diffuse large B-cell lymphoma, leg type →